Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Operating Expenses (2017 - 2025)

Historic Operating Expenses for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to $51.1 million.

  • Protagonist Therapeutics' Operating Expenses rose 1085.02% to $51.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $190.2 million, marking a year-over-year increase of 888.81%. This contributed to the annual value of $181.6 million for FY2024, which is 1818.26% up from last year.
  • As of Q3 2025, Protagonist Therapeutics' Operating Expenses stood at $51.1 million, which was up 1085.02% from $47.6 million recorded in Q2 2025.
  • Protagonist Therapeutics' Operating Expenses' 5-year high stood at $51.1 million during Q3 2025, with a 5-year trough of $30.2 million in Q1 2021.
  • For the 5-year period, Protagonist Therapeutics' Operating Expenses averaged around $41.7 million, with its median value being $43.0 million (2024).
  • Per our database at Business Quant, Protagonist Therapeutics' Operating Expenses surged by 11168.25% in 2021 and then tumbled by 2693.61% in 2022.
  • Over the past 5 years, Protagonist Therapeutics' Operating Expenses (Quarter) stood at $45.6 million in 2021, then dropped by 19.98% to $36.5 million in 2022, then rose by 1.19% to $37.0 million in 2023, then increased by 18.69% to $43.9 million in 2024, then increased by 16.59% to $51.1 million in 2025.
  • Its Operating Expenses stands at $51.1 million for Q3 2025, versus $47.6 million for Q2 2025 and $47.6 million for Q1 2025.